Related Experiment Video
Updated: Jun 5, 2026
06:08
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
New indicator for prostate gland biopsy when malignancy is in question
1Department of Radiology, Jordan University Hospital, Amman, Jordan. Azmi11946@yahoo.com
Summary
A new prostate biopsy index, combining prostate volume, age, and free PSA, shows superior accuracy over PSA alone. This novel indicator can significantly improve patient selection for prostate biopsies, potentially avoiding unnecessary procedures.
Area of Science:
- Urology
- Oncology
- Medical Diagnostics
Background:
- Elevated prostate-specific antigen (PSA) levels and digital rectal exam findings often prompt prostate biopsies.
- Current diagnostic methods for prostate cancer selection have limitations in specificity, leading to unnecessary biopsies.
Purpose of the Study:
- To develop and validate a novel Prostate Biopsy Index (PBI) with higher specificity than PSA for improved patient selection.
- To compare the diagnostic performance of the PBI against existing parameters in patients undergoing prostate biopsy.
Main Methods:
- A cohort of 135 patients with elevated PSA and/or palpable nodules underwent trans-rectal ultrasound-guided prostate biopsy.
- A new formula integrating prostate volume, patient age, and free PSA was devised as the Prostate Biopsy Index (PBI).
- Receiver Operating Characteristic (ROC) curve analysis was used to compare the PBI with other parameters.
Main Results:
- Prostate cancer was diagnosed in 30% of patients.
- The PBI demonstrated a significant difference between malignant and non-malignant groups (P = 0.01).
- ROC analysis revealed the PBI's superior performance (AUC, P = 0.001) compared to other parameters, especially in PSA ranges of ≤10 ng/mL and 10.1-20 ng/mL.
Conclusions:
- The novel Prostate Biopsy Index (PBI) exhibits superior diagnostic performance compared to currently used parameters.
- The PBI can significantly enhance the selection of patients for prostate biopsy, potentially reducing unnecessary procedures by up to 63.5% in specific PSA ranges.
